Why Are Apellis Pharmaceuticals Shares More Than 20% Down Today?

Apellis Pharmaceuticals Inc APLS shares are trading lower amid safety concerns regarding the company's newly launched Syfovre (pegcetacoplan injection) for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Raymond James analyst notes that the ASRS Research and Safety in Therapeutics (ReST) Committee distributed a notification to its members on Saturday indicating:

  • Six cases of occlusive retinal vasculitis have been observed since Syfovre's launch in March this year.
  • All events observed after the first injection, 7-13 days post-injection.
  •  No specific product lots were implicated. 

Moreover, the communication indicates that ~60,000 vials of Syfovre have been distributed since FDA approval. 

The analyst spoke with Apellis, who confirmed the details. 

The 60k vials distributed since launch exceeds the already Street-high 2Q23 estimate by ~15k vials, implying 2Q23 Syfovre revenue could be over $80 million (vs. Raymond James's estimate of $54 million and Street consensus $34 million).

In Q1 FY23, Apellis reported $18.4 million in Syfovre U.S. net product revenue.

Price Action: APLS shares are down 22.80% at $65.25 on the last check Monday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorNewsHealth CareAnalyst RatingsMoversTrading IdeasGeneralBriefsExpert Ideaswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!